

Aalborg Universitet

Heart rate variability in atrial fibrillation

the balance between sympathetic and parasympathetic nervous system

Khan, Ahsan A; Lip, Gregory Y H; Shantsila, Alena

Published in: European Journal of Clinical Investigation

DOI (link to publication from Publisher): 10.1111/eci.13174

Publication date: 2019

Document Version Accepted author manuscript, peer reviewed version

Link to publication from Aalborg University

Citation for published version (APA):

Khan, A. A., Lip, G. Y. H., & Shantsila, A. (2019). Heart rate variability in atrial fibrillation: the balance between sympathetic and parasympathetic nervous system. European Journal of Clinical Investigation, 49(11), [e13174]. https://doi.org/10.1111/eci.13174

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- ? You may not further distribute the material or use it for any profit-making activity or commercial gain ? You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

DR. AHSAN AFTAB KHAN (Orcid ID : 0000-0003-1617-1464)

Article type : Review

REVIEW

Heart rate variability in atrial fibrillation: the balance between sympathetic and parasympathetic nervous system

Ahsan A Khan, MRCP¹

Gregory Y.H. Lip, MD ^{2,3}

Alena Shantsila, PhD²

- 1. Institute of Applied Health Research, University of Birmingham, United Kingdom
- 2. Liverpool Centre for Cardiovascular Science, University of Liverpool, United Kingdom
- 3. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.

Correspondence to:

Dr Alena Shantsila s.shantsila@liverpool.ac.uk

Full mailing address University of Liverpool

William Henry Duncan Building

6 West Derby Street

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi: 10.1111/ECI.13174</u>

This article is protected by copyright. All rights reserved

Liverpool, L7 8TX

Telephone number0151 794 9020

Word count: 2243 (not including abstract, figures, tables and references)

Abstract

Background: Atrial fibrillation (AF) is the commonest abnormal heart rhythm with significant related morbidity and mortality. Several pathophysiologic mechanisms have been advocated to explain the onset of AF. There has been increasing evidence that abnormalities of the autonomic nervous system (ANS) that includes sympathetic, parasympathetic and intrinsic neural network are involved in the pathogenesis of AF. This review will consider the anatomical and pathophysiological concepts of the cardiac neuronal network and discuss how it can be investigated.

Design: Relevant articles for this review were selected primarily from Ovid Medline and Embase databases. We searched for key terms 'atrial fibrillation', 'AF', 'autonomic dysfunction' 'autonomic nervous system' 'heart rate variability' and 'HRV' to gather relevant studies. Duplicate papers were excluded.

Results: Heart is richly innervated by autonomic nerves. Both sympathetic and parasympathetic system interact in developing AF along with cardiac ganglionated plexi (GP). Thus autonomic dysfunction is present in AF. There are methods including selective ablation that reduce autonomic innervation and show to reduce the incidence of spontaneous or induced atrial arrhythmias. Heart rate variability (HRV) is a useful tool to assess sympathetic and parasympathetic influences on disease states. HRV can be improved following intervention and is thus a useful application in assessing autonomic dysfunction in patients with AF.

Conclusion: ANS plays a crucial role in the development, propagation and complexity of AF. Assessment of the autonomic involvement in the propagation of AF may help in explaining why certain patients with AF do not benefit from cardioversion or ablation.

Keywords: Autonomic nervous system; heart rate; autonomic dysfunction; vagal tone; atrial fibrillation

Introduction

Atrial fibrillation (AF) is the commonest abnormal heart rhythm with significant related morbidity and mortality. From the general population, 1-2% is affected by AF, however the prevalence of this condition rises to approximately 10% in individuals aged > 75 years.¹⁻³ There were 8.8 million adults with established AF in 2010 in Europe and this is expected to increase to 17.9 million by 2060.³ AF is an independent risk factor for stroke.⁴ It is associated with a 5-fold increase in the risk of stroke, a 3-fold increase in the risk of heart failure and a 2-fold increase in the risk of death.^{1, 5}

Several pathophysiologic mechanisms (such as neurohormonal activation, structural changes, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of AF.⁶ There has been increasing evidence that abnormalities of the autonomic nervous system (ANS) that includes sympathetic, parasympathetic and intrinsic neural network are involved in the pathogenesis of AF.⁷ This review will consider the anatomical and pathophysiological concepts of the cardiac neuronal network and discuss how it can be investigated.


Anatomy of the cardiac autonomic nervous system

The heart is richly innervated by the autonomic nerves. The ANS of the heart consists of intrinsic and extrinsic ganglia.⁸ The parasympathetic components of the extrinsic cardiac nervous system originate in the vagus nerve. The extrinsic sympathetic innervation is mediated via the cervical, stellate (cervicothoracic), and thoracic ganglia. Interestingly, vagus nerve also contains sympathetic fibres and conversely, parasympathetic fibres are also found in sympathetic nerves.⁹⁻¹¹

Baroreceptors, chemoreceptors and mechanical stress receptors located in the heart and great vessels regulate autonomic tone.⁸ Moreover, clusters of intrinsic ganglia form a complex neural network composed of ganglionated plexi (GP), which are situated in the atria in multiple locations and attenuate the interactions between the extrinsic and intrinsic nervous systems (see figure 1).¹² GP are suitably innervated with both adrenergic and vagal nerve endings and are situated in fat pads, close to the pulmonary vein ostia. The cardiac neural control occurs at

several levels with each level capable of parallel processing of afferent neurotransmission and efferent cardiac sympathetic outflow.¹³

Figure 1 – Cross sectional drawing of the heart showing the anatomical position of Ganglionated plexi (GP) (image obtained from Armour *et al* with permission)¹⁴



G.P = Ganglionated plexus, PA = Pulmonary artery, SVC = Superior vena cava, IVC = Inferior vena cava.

Autonomic dysfunction in atrial fibrillation

There has been detailed exploration into the autonomic mechanisms underlying AF. Scherf and colleagues first proposed the theory of focal firing based on their observations that rapid firing of action potentials and/or AF occurred following application of either acetylcholine (ACh) or aconitine and it terminated once the source was removed by cooling.^{15, 16} Studies by Moe *et al* further demonstrated that AF could be initiated by premature beats during stimulation of the vagus nerve.¹⁷ Other basic science studies also showed that electrical stimulation of autonomic nerves innervating the heart could induce AF.^{18, 19}

Sympathetic system promote arrhythmia by increasing calcium transient in the synapses.²⁰ Calcium entry into the presynaptic neuron through voltage gated calcium channels is essential for neurotransmitter release. Activated β -adrenergic signal pathways increase calcium entry into the presynaptic neuron and the spontaneous release of calcium from sarcoplasmic reticulum.²⁰ This leads to neurotransmitter release and thus increase in action potential frequency.

On the other hand, vagal stimulation contributes to development of AF by heterogenous shortening of action potential duration and refractory period.⁷ ACh activates the muscarinic receptors (mainly M2 in the heart). This in turn modulate cardiac ionic channels through direct activation of I_{KACh} (inward-rectifying potassium channel). I_{KACh} is a G protein-gated ion channel found in the sinoatrial node and atria and contributes to the regulation of heart rate by accelerating repolarisation and leading to hyperpolarisation. It also exerts its effect through indirect regulation by modulation of cyclic adenosine monophosphate (cAMP) mediated responses, a second messenger used for intracellular signal transduction (such as transferring into cells the effects of hormones like glucagon and adrenaline, which cannot pass through the plasma membrane).^{21, 22} The overall result is shortening of action potential duration leading to AF.

Vagal stimulation has also been shown to cause conduction delays.^{23, 24} Additionally, recent studies have shown evidence of noncholinergic vagal effects that may also contribute to the pathogenesis of vagally induced AF.^{25, 26} These effects may be mediated by vagally released

polypeptide and vasoactive intestinal polypeptide (VIP), which enhance the delayed rectifier potassium current (I_{Ks}) and decrease sodium current and thus contribute to the vagal effects on atrial action potential duration and conduction velocities as well as increased propensity to AF.⁷

It has been demonstrated that there is significant vagal innervation of the atrial muscle sleeves extending into the pulmonary veins and other thoracic veins.²⁷ In normal heart, vagal influences are predominant, thus explaining that the clinical manifestation of vagal-mediated paroxysmal AF is preferentially seen in young male adults with absence of detectable heart disease.²⁸ Their electrocardiogram (ECG) pattern is of common flutter alternating with fibrillation.²⁸ Vagally mediated AF occurs more commonly in men than in women, and the onset of first episode is around 30 – 50 years of age.²⁸ Sympathetically mediated AF is less common and observed in the presence of any heart disease, the first effect of which is to induce vagal withdrawal.²⁸

The anatomical distribution of the autonomic fibres is different for sympathetic and vagal innervation.²⁸ Sympathetic and parasympathetic terminals lie in close proximity to one another, and both are close to the target cells, yet do not have an identical distribution.²⁸ Thus stimulation of one system may affect function of the other.²⁸ For example, noradrenaline release from sympathetic nerves is diminished by the acetylcholine released from neighbouring vagal nerves.²⁸ Furthermore, the latency time and duration of the physiological response of each sympathetic and parasympathetic also differs.²⁸ The functional response to cholinergic stimulation occur within a few milliseconds whereas adrenergic stimulation requires seconds for target activastion.²⁸ This combination of inhomogeneity of the autonomic effects in space and time contributes to the difficulty in managing AF.

Previously, it was considered that sympathetic nervous system (SNS) drove most of exerciseinduced AF; however Coumel and colleagues describe that electrophysiological characteristics of atrial cells (including action potential duration and refractoriness, conduction speed) are modulated differently by sympathetic and vagal influences.²⁸ The former tends to favour abnormal automaticity and triggered activity whereas the latter tends to influence macro reentry phenomena.²⁸ Other studies have shown that both sympathetic and parasympathetic system interact in developing AF.^{29, 30} Additionally, cardiac GP may play a vital role in the pathogenesis of AF.⁷ Clinically, the sites of ablation during PV isolation are often adjacent to the locations of GPs and PV isolation could lead to vagal denervation of the left atrium. Platt and colleagues were the first to describe that ablation of GPs may aid in terminating AF.³¹ This was further supported by other studies, demonstrating the feasibility of selectively targeting GPs to suppress AF.^{7, 32} Katritsis *et al* concluded that combination of PV isolation and GP ablation has higher success in suppressing AF when compared to PV isolation alone.³³

There is evidence to support that in addition to the atrial remodelling that takes place in patients with AF leading to 'AF begets AF' hypothesis; there is structural remodelling (apoptosis and scaring) and autonomic remodelling, all of which promote the propensity and prolongation of AF episodes.^{34, 35} The exact extent and mechanism(s) of such neural remodelling remain elusive. It is clear that autonomic dysfunction plays an important role in the pathogenesis of AF. There are methods that reduce autonomic innervation and thus show to reduce the incidence of spontaneous or induced atrial arrhythmias.³⁶⁻⁴⁰ This suggests that neuromodulation may be helpful in controlling AF. Studies looking at altering of the sympathetic limb of ANS showed that suppression of sympathetic tone leads to a notable reduction in atrial vulnerability to AF induction and post-ablation AF recurrence.^{41, 42}

Role of heart rate variability

Exploring the ANS is possible through heart rate variability (HRV) evaluation. It is well established that short-term, respiratory related variation of cardiac cycle reflects vagal activity, whereas variation over prolonged periods reflect neurogenic and humoral modulation of the sympathetic tone.⁴³ HRV is a non-invasive method to evaluate ANS activity and reflects the best ANS influence on heart rate.⁴⁴⁻⁴⁶ HRV is a measure which indicates the variation in the heartbeat within a specific time frame. It is measured by looking at the heart rate that changes over time against the average heart rate, and is expressed as time and spectrum analytical methods.⁴⁷ It analyses variation in the beat to beat intervals of the heart and reflects the parasympathetic nervous system (PNS) and SNS balance.⁴⁸ Variations in heart rate may be evaluated by a number of

methods but the commonly used methods in HRV are time domain and frequency domain. The most commonly used measures of each domain are presented in table 1.

Time domain indices of HRV quantify the amount of variability in measurements of the interbeat interval (IBI), which is the time period between successive heartbeats.⁴⁸ Some of the common time domain metrics include SDNN, SDNN Index (SDNNI), RMSSD, NN50 and pNN50. Briefly, SDNN is the sum contribution of both SNS and PNS. It is more accurate when calculated over 24 hours than during shorter periods and is the gold standard for medical stratification of cardiac risk when recorded over a 24 hour period.⁴³ SDNN values predict both morbidity and mortality. Based on 24 hour recording, patients with SDNN values below 50 ms are classified as unhealthy, 50 – 100 ms have compromised health, and above 100 ms are healthy.⁴⁹

SDANNI reflects autonomic influence on HRV and correlates with VLF power over a 24 hour period. RMSSD reflects the beat-to-beat variance in HR and is the primary time-domain measure used to estimate the vagally mediated changes reflected in HRV.⁵⁰ 24 hour RMSSD measurements strongly correlate with pNN50 and HF power.⁵¹ The RMSSD is more influenced by the PNS than SDNN. Lower RMSSD values correlate with high risk of sudden unexplained death in epilepsy.⁵²

Frequency domain measurements are analogous to the electroencephalogram (EEG) where autoregressive modelling is used to separate HRV into its component ULF, VLF, LF and HF rhythms that operate within different frequency ranges. This concept is similar to a prism that reflects light into its component wavelengths.⁴³ It includes ULF, VLF, LF, HF and LF/HF ratio. Briefly, ULF correlates highly with SDANN time-domain index and represents very slow-acting biological processes, core body temperature, metabolism and the renin-angiotensin system. VLF is more strongly associated with all cause mortality than LF or HF. Low VLF power has been associated with arrhythmic death, post traumatic stress disorder (PTSD), high inflammation, low levels of testosterone, heart's intrinsic nervous system, physical activity, thermoregulatory, renin-angiotensin and endothelial influences on the heart.^{50, 53-59} PNS activity may contribute to VLF power since parasympathetic blockade almost completely abolishes it whereas SNS does not influence VLF power.^{43, 60}

In contrast, LF power is produced by both PNS and SNS as well as blood pressure regulation via baroreceptors.^{43, 58, 61} However, PNS is predominant in LF. Respiratory-related efferent vagally mediated influences are particularly present in the LF band, for example when taking a deep breath or sigh.⁶² The HF band reflects parasympathetic activity and is also referred to as the respiratory band as it corresponds to the heart rate variations related to the respiratory cycle. HF power is highly correlated with the pNN50 and RMSSD time-domain measures.⁶³ HF power may increase at night and decrease during the day.⁶⁴ Lower HF power is related to stress, panic or anxiety.

It is believed that an increase of the PNS tone increases HRV while a vagal withdrawal may reduce HRV.^{44-46, 65} Low HRV is indicative of reduced cardiac parasympathetic function and is associated with worse cardiovascular outcomes.^{53, 66} In sinus rhythm, high HRV signifies a good cardiovascular adaptive response to various endogenous and exogenous factors.⁴⁷ HRV is found to be lower in several cardiac and non cardiac disease states including coronary artery disease, congestive heart failure, hypertension, rheumatoid arthritis, aging and diabetic neuropathy amongst other.^{49, 53, 66-68} In the absence of direct intraneural recordings of cardiac autonomic activity in humans, HRV analysis has provided a useful indirect surrogate.⁶⁹

AF is characterised by marked HRV. The patterns of atrial excitation in AF, the conduction properties of the atrioventricular node and the modulating effects of the ANS appear to be influential.⁷⁰⁻⁷³ HRV has been studied extensively in patients with normal sinus rhythm and shown to have important prognostic implications for various cardiovascular disorders (see table 2).^{44, 49, 53, 74, 75} However, there have been relatively few published reports dealing with the phenomenon in AF.^{73, 76, 77} A study by Friedman showed that increasing left atrial size was associated with less HRV, suggesting a role of the left atrium in modulating the cardiovascular effects of the ANS.⁷⁸ Other studies have shown use of HRV in AF and described that HRV indices correlate well with vagal tone.^{47, 73} They concluded that HRV in patients with AF is related to vagal tone.^{47, 73} HRV is thus a useful way of assessing autonomic dysfunction in patients with AF.

Conclusion

The evidence shows that ANS plays a crucial role in the development, propagation and complexity of AF. The mechanisms underlying the process of autonomic dysfunction within the myocardium are intricate and perhaps, this explains why this concept has not received enough recognition. Assessment of the autonomic involvement in the propagation of AF may help in explaining why certain patients with AF do not benefit from cardioversion or ablation. The advent of non invasive techniques, such as heart rate variability has allowed to assess the role of ANS in AF in greater detail. There is further data to support that modulation of the ANS is possible and prudent. This may prove to be a useful addition in the management of AF along with existing therapy.

Disclosures

AAK has no financial interest in the subject matter or materials discussed. AS has no financial interest in the subject matter or materials discussed. GYHL has served as a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo; and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. No personal fees received.

References

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B and Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893-2962.

2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV and Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285:2370-5.

3. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH and Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J.* 2013;34:2746-51.

4. Wolf PA, Abbott RD and Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991;22:983-8.

5. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM and Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. 2014;130:2071-104.

6. Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, Parati G, Redon J, Schmieder R, Tsioufis C and Mancia G. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. *J Hypertens*. 2012;30:239-52.

7. Xi Y and Cheng J. Dysfunction of the autonomic nervous system in atrial fibrillation. *J Thorac Dis*. 2015;7:193-198.

 Kapa S, Venkatachalam KL and Asirvatham SJ. The autonomic nervous system in cardiac electrophysiology: an elegant interaction and emerging concepts. *Cardiol Rev.* 2010;18:275-84.
 Randall WC, Szentivanyi M, Pace JB, Wechsler JS and Kaye MP. Patterns of sympathetic nerve projections onto the canine heart. *Circ Res.* 1968;22:315-23.

10. Kawashima T. The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution. *Anat Embryol (Berl)*. 2005;209:425-38.

11. Seki A, Green HR, Lee TD, Hong L, Tan J, Vinters HV, Chen PS and Fishbein MC. Sympathetic nerve fibers in human cervical and thoracic vagus nerves. *Heart Rhythm*. 2014;11:1411-7.

12. Hou Y, Scherlag BJ, Lin J, Zhang Y, Lu Z, Truong K, Patterson E, Lazzara R, Jackman WM and Po SS. Ganglionated plexi modulate extrinsic cardiac autonomic nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of atrial fibrillation. *J Am Coll Cardiol*. 2007;50:61-8.

13. Esler M. Looking at the sympathetic nervous system as a primary source. In: M. Houston, ed. *Handbook of Hypertension*; 2004(22): 81 - 102.

14. Armour JA, Murphy DA, Yuan B-X, MacDonald S and Hopkins DA. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. *The Anatomical Record*. 1997;247:289-298.

15. Scherf D, Morgenbesser LJ, Nightingale EJ and Schaeffeler KT. Further studies on mechanism of auricular fibrillation. *Proc Soc Exp Biol Med*. 1950;73:650-4.

16. Scherf D. Studies on auricular tachycardia caused by aconitine administration. *Proc Soc Exp Biol Med*. 1947;64:233-9.

17. Moe GK and Mendez C. Basis of pharmacotherapy of cardiac arrhythmias. *Mod Concepts Cardiovasc Dis*. 1962;31:739-44.

18. Lewis T, Drury A and Bulger H. Observations upon atrial flutter and fibrillation. VI. Refractory period and rate of propagation in the auricle: Their relation to block in the auricular walls and to flutter. *Heart*. 1921;8:84 - 134.

19. Hoff HE and Geddes LA. Cholinergic Factor in Auricular Fibrillation. J Appl Physiol. 1955;8:177-192.

20. Francis GS. Modulation of peripheral sympathetic nerve transmission. *J Am Coll Cardiol*. 1988;12:250-4.

21. Mark MD and Herlitze S. G-protein mediated gating of inward-rectifier K+ channels. *Eur J Biochem*. 2000;267:5830-5836.

22. Harvey RD and Belevych AE. Muscarinic regulation of cardiac ion channels. *Br J Pharmacol*. 2003;139:1074-84.

23. Rosenshtraukh LV, Zaitsev AV, Fast VG, Pertsov AM and Krinsky VI. Vagally induced block and delayed conduction as a mechanism for circus movement tachycardia in frog atria. *Circ Res.* 1989;64:213-26.

24. Hirose M, Carlson MD and Laurita KR. Cellular mechanisms of vagally mediated atrial tachyarrhythmia in isolated arterially perfused canine right atria. *J Cardiovasc Electrophysiol*. 2002;13:918-26.

25. Yang D, Xi Y, Ai T, Wu G, Sun J, Razavi M, Delapasse S, Shurail M, Gao L, Mathuria N, Elayda M and Cheng J. Vagal stimulation promotes atrial electrical remodeling induced by rapid atrial pacing in dogs: evidence of a noncholinergic effect. *Pacing Clin Electrophysiol*. 2011;34:1092-9. 26. Liu Y, Scherlag BJ, Fan Y, Varma V, Male S, Chaudhry MA, Huang C and Po SS. Inducibility of atrial fibrillation after GP ablations and "autonomic blockade": evidence for the pathophysiological role of the nonadrenergic and noncholinergic neurotransmitters. *J Cardiovasc Electrophysiol*. 2013;24:188-95.

27. Zipes DP and Knope RF. Electrical properties of the thoracic veins. Am J Cardiol. 1972;29:372-6.

28. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? *Eur Heart J.* 1994;15 Suppl A:9-16.

29. Chen PS, Chen LS, Fishbein MC, Lin SF and Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res.* 2014;114:1500-15.

30. Chou CC and Chen PS. New concepts in atrial fibrillation: mechanism and remodeling. *Med Clin North Am*. 2008;92:53-63, x.

31. Platt M, R M and Scherlag BJ. Limiting the number and extent of radiofrequency applications to terminate atrial fibrillation and subsequently prevent its inducibility. *Heart Rhythm.* 2004:S11.

32. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, Khunnawat C and Ngarmukos T. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. *J Am Coll Cardiol*. 2004;43:2044-53.

33. Katritsis D, Sougiannis D, Batsikas K, Giazitzoglou E, Mersinias J, Katritsis G and Po SS. Autonomic modulation of complex fractionated atrial electrograms in patients with paroxysmal atrial fibrillation. *J Interv Card Electrophysiol*. 2011;31:217-23.

34. Wijffels MC, Kirchhof CJ, Dorland R and Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation*. 1995;92:1954-68.

35. Zheng S, Zhang Y, Wang Z, Li Z, Hou X, Duan W and Hou Y. Autonomic neural remodeling of the pulmonary vein-left atrium junction in a prolonged right atrial pacing canine model. *Pacing Clin Electrophysiol*. 2014;37:745-50.

36. Leiria TL, Glavinovic T, Armour JA, Cardinal R, de Lima GG and Kus T. Longterm effects of cardiac mediastinal nerve cryoablation on neural inducibility of atrial fibrillation in canines. *Auton Neurosci*. 2011;161:68-74.

 Richer LP, Vinet A, Kus T, Cardinal R, Ardell JL and Armour JA. Alpha-adrenoceptor blockade modifies neurally induced atrial arrhythmias. *Am J Physiol Regul Integr Comp Physiol*. 2008;295:R1175-80.
 Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, Fishbein MC, Lin SF, Chen LS and Chen PS. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. *Circulation*. 2008;118:916-25.

39. Shen MJ, Shinohara T, Park HW, Frick K, Ice DS, Choi EK, Han S, Maruyama M, Sharma R, Shen C, Fishbein MC, Chen LS, Lopshire JC, Zipes DP, Lin SF and Chen PS. Continuous low-level vagus nerve

stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. *Circulation*. 2011;123:2204-12.

40. Wang X, Zhao Q, Huang H, Tang Y, Xiao J, Dai Z, Yu S and Huang C. Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing. *PLoS One*. 2013;8:e64611.

41. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K and Bohm M. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. *Hypertension*. 2012;60:172-8.

42. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S and Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. *J Am Coll Cardiol*. 2012;60:1163-70.

43. Malik M. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation*. 1996;93:1043-65.

44. Force ET. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation*. 1996;93:1043-65.

45. Sredniawa B, Musialik-Lydka A, Herdynska-Was M and Pasyk S. [The assessment and clinical significance of heart rate variability]. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 1999;7:283-8.

46. Sztajzel J. Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system. *Swiss Med Wkly*. 2004;134:514-22.

47. Barauskiene V, Rumbinaite E, Karuzas A, Martinkute E and Puodziukynas A. Importance of Heart Rate Variability in Patients with Atrial Fibrillation. *J Cardiol Clin Res.* 2016;4:1080.

48. Shaffer F and Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. *Front Public Health*. 2017;5:258-258.

49. Kleiger RE, Miller JP, Bigger JT, Jr. and Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol*. 1987;59:256-62.

50. Shaffer F, McCraty R and Zerr CL. A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. *Front Psychol*. 2014;5:1040.

51. Bigger JT, Jr., Albrecht P, Steinman RC, Rolnitzky LM, Fleiss JL and Cohen RJ. Comparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction. *Am J Cardiol*. 1989;64:536-8.

52. DeGiorgio CM, Miller P, Meymandi S, Chin A, Epps J, Gordon S, Gornbein J and Harper RM. RMSSD, a measure of vagus-mediated heart rate variability, is associated with risk factors for SUDEP: the SUDEP-7 Inventory. *Epilepsy Behav*. 2010;19:78-81.

53. Bigger JT, Jr., Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE and Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. *Circulation*. 1992;85:164-71.

54. Shah AJ, Lampert R, Goldberg J, Veledar E, Bremner JD and Vaccarino V. Posttraumatic stress disorder and impaired autonomic modulation in male twins. *Biol Psychiatry*. 2013;73:1103-10.

55. Lampert R, Bremner JD, Su S, Miller A, Lee F, Cheema F, Goldberg J and Vaccarino V. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. *Am Heart J*. 2008;156:759.e1-7.

56. Theorell T, Liljeholm-Johansson Y, Bjork H and Ericson M. Saliva testosterone and heart rate variability in the professional symphony orchestra after "public faintings" of an orchestra member. *Psychoneuroendocrinology*. 2007;32:660-8.

57. Bernardi L, Valle F, Coco M, Calciati A and Sleight P. Physical activity influences heart rate variability and very-low-frequency components in Holter electrocardiograms. *Cardiovasc Res.* 1996;32:234-7.
58. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC and Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. *Science*. 1981;213:220-2.

59. Claydon VE and Krassioukov AV. Clinical correlates of frequency analyses of cardiovascular control after spinal cord injury. *Am J Physiol Heart Circ Physiol*. 2008;294:H668-78.

60. Taylor JA, Carr DL, Myers CW and Eckberg DL. Mechanisms underlying very-low-frequency RR-interval oscillations in humans. *Circulation*. 1998;98:547-55.

61. Berntson GG, Cacioppo JT and Grossman P. Whither vagal tone. Biol Psychol. 2007;74:295-300.

62. Tiller WA, McCraty R and Atkinson M. Cardiac coherence: a new, noninvasive measure of autonomic nervous system order. *Altern Ther Health Med*. 1996;2:52-65.

63. Kleiger RE, Stein PK and Bigger JT, Jr. Heart rate variability: measurement and clinical utility. *Ann Noninvasive Electrocardiol*. 2005;10:88-101.

64. McCraty R and Shaffer F. Heart Rate Variability: New Perspectives on Physiological Mechanisms,
Assessment of Self-regulatory Capacity, and Health risk. *Global advances in health and medicine*.
2015;4:46-61.

65. Coumel P. Autonomic arrhythmogenic factors fibrillation in paroxysmal atrial fibrillation. In: A. M. Olsson S, Campbell R, ed. *Atrial: mechanisms and therapeutic strategies* New York: Futura Publishing; 1994: 171-185.

66. La Rovere MT, Bigger JT, Jr., Marcus FI, Mortara A and Schwartz PJ. Baroreflex sensitivity and heartrate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet*. 1998;351:478-84.

67. Singh JP, Larson MG, Tsuji H, Evans JC, O'Donnell CJ and Levy D. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. *Hypertension*. 1998;32:293-7.

68. Adlan AM, Lip GY, Paton JF, Kitas GD and Fisher JP. Autonomic function and rheumatoid arthritis: a systematic review. *Semin Arthritis Rheum*. 2014;44:283-304.

69. Adlan AM, Veldhuijzen van Zanten J, Lip GYH, Paton JFR, Kitas GD and Fisher JP. Cardiovascular autonomic regulation, inflammation and pain in rheumatoid arthritis. *Auton Neurosci*. 2017;208:137-145.
70. Stein KM, Walden J, Lippman N and Lerman BB. Ventricular response in atrial fibrillation: random or deterministic? *Am J Physiol*. 1999;277:H452-8.

71. Kirsh JA, Sahakian AV, Baerman JM and Swiryn S. Ventricular response to atrial fibrillation: role of atrioventricular conduction pathways. *J Am Coll Cardiol*. 1988;12:1265-72.

72. Toivonen L, Kadish A, Kou W and Morady F. Determinants of the ventricular rate during atrial fibrillation. *J Am Coll Cardiol*. 1990;16:1194-200.

73. van den Berg MP, Haaksma J, Brouwer J, Tieleman RG, Mulder G and Crijns HJ. Heart rate variability in patients with atrial fibrillation is related to vagal tone. *Circulation*. 1997;96:1209-16.

74. Stein KM, Borer JS, Hochreiter C, Okin PM, Herrold EM, Devereux RB and Kligfield P. Prognostic value and physiological correlates of heart rate variability in chronic severe mitral regurgitation. *Circulation*. 1993;88:127-35.

75. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, Eckberg DL, Zaman AG, Williams S, Neilson JM and Nolan J. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. *J Am Coll Cardiol*. 2002;40:1801-8.
76. Stein KM, Borer JS, Hochreiter C, Devereux RB and Kligfield P. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral reurgitation. *The American Journal of Cardiology*. 1994;74:906-911.

77. Frey B, Heinz G, Binder T, Wutte M, Schneider B, Schmidinger H, Weber H and Pacher R. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. *Am Heart J*. 1995;129:58-65.

78. Friedman HS. Heart rate variability in atrial fibrillation related to left atrial size. *Am J Cardiol*. 2004;93:705-709.

Table 1 – Common time domain and frequency domain measures of HRV (adapted from Malik *et al*)⁴⁸

Variable	Units	Description
Time domain	measure	es
NN interval	ms	Normal to normal interval
SDNN	ms	Standard deviation of all NN intervals.
SDANN	ms	Standard deviation of the averages of NN intervals in all 5 min
		segments of the entire recording.
RMSSD	ms	The square root of the mean of the sum of the squares of differences
		between adjacent NN intervals.
SDNN index	ms	Mean of the standard deviations of all NN intervals for all 5 min
		segments of the entire recording.
SDSD	ms	Standard deviation of differences between adjacent NN intervals.
NN50 count	ms	Number of pairs of adjacent NN intervals differing by more than 50
		ms in the entire recording. Three variants are possible, counting all
		such NN intervals pairs or only pairs in which the first or the second
		interval is longer.
pNN50	%	NN50 count divided by the total number of all NN intervals.
Frequency do	main me	easures
5 min total	ms ²	The variance of NN intervals over the temporal segment [Frequency
power		range: \leq 0.4 Hz]
ULF	ms ²	Power in the ultra low frequency range [Frequency range: \leq 0.003
		Hz]
VLF	ms ²	Power in very low frequency range [Frequency range: \leq 0.04 Hz]
LF	ms ²	Power in low frequency range [Frequency range: 0.04 – 0.15 Hz]
LF norm	n.u.	LF power in normalised units. LF/Total Power-VLF) x 100
HF	ms ²	Power in high frequency range [Frequency range: 0.15 – 0.4 Hz]
HF norm	n.u.	HF power in normalised units. HF/Total Power-VLF) x 100
LF/HF	ms²/	Ratio of low frequency range and high frequency range
	ms²	

This article is protected by copyright. All rights reserved

Table 2 – Utility of HRV in cardiovascular disease states and risk factor conditions

Year	Condition	Number	Summary
	studied	of	
		patients	
et 2019	Coronary	100	Complete revascularisation during
	artery disease		coronary angiography associated with
	(CAD)		improved HRV (p<0.001).
⁵⁵ 2017	Rheumatoid	63	Time (RMSSD, pNN50%) and frequency
	arthritis		(high frequency (HF) power, low
			frequency (LF) power, total power)
			domain measures of HRV were lower in
			the RA, RA-hypertension and
			hypertension groups compared to
			controls (p=0.001). High sensitivity CRP
			(hs-CRP) and pain were independently
			and inversely associated with time
			domain parameters of HRV.
e 2016	Atrial	222	HRV significantly lower in AF patients
	fibrillation		(p<0.05). HRV was significantly higher in
	(AF)		patients on betablockers than without
			(p<0.005).
1992	CAD	715	Each measure of HRV had a significant
			and at least moderately strong univariate
			association with all-cause mortality,
			cardiac death and arrhythmic death.
3 1995	Heart failure	35	SDANN was independently associated
	(HF) and AF		with survival on multivariate analysis.
			Dichotomized SDANN at 100 msec
			accurately predicted 12-month survival in
			28 patients (relative risk = 9.77, p=0.001)
	et 2019 55 2017 e 2016 1992	studied2019Coronary artery disease (CAD)2017Rheumatoid arthritis2017Rheumatoid arthritis92017Rheumatoid arthritis92017Rheumatoid arthritis92016Atrial fibrillation (AF)91992CAD91995Heart failure	studiedof patients2019Coronary artery disease (CAD)100352017Rheumatoid arthritis63352017Rheumatoid arthritis63362017Rheumatoid arthritis63372016Atrial (AF)22231992CAD71531995Heart failure35

Friedman ⁶⁴	2004	AF	38	Reduced HRV correlated with increasing
Theaman	2001	7.1	30	left atrial and left ventricular dimensions.
				Left atrial dimension is an independent
				determinant of HRV. HRV greater in lone
				AF than other cardiac disorders.
Kearney et	2002	HF	553	SDNN independent predictor of all-cause
al ⁶¹				mortality. Hazard ratio (HR) of
				progressive HF death for a 10% decrease
				in SDNN was 1.06 (95% Confidence
				Interval (CI) 1.01-1.12).
Kleiger <i>et</i>	1987	CAD	808	SDNN had the strongest univariate
al ⁵⁴				correlation with mortality of all Holter
				variables. Relative risk of mortality was
				5.3 times higher in the group with SDNN
				< 50ms than the group with SDNN >
				100ms.
La Rovere <i>et</i>	1998	CAD	1284	SDNN < 70ms carried a significant
al ⁵¹				multivariate risk of cardiac mortality (3.2
				[95% CI 1.42-7.36])
Marinkovic	2019	Paroxysmal AF	100	HRV changes during the 3-month period
et al ⁶⁶		(PAF)		after catheter ablation for PAF may
				predict long-term outcomes. SDNN cut-
				off value of 62.5 ms showed the best
				predictive ability for late recurrence AF
				(Area Under Curve (AUC) = 0.59 [95% Cl
				0.27-0.49], p = 0.04)
Mori <i>et al⁶⁷</i>	2018	AF	54	Marked increase in HRV parameters
				observed immediately post cryoballoon
				ablation (CB) especially in patients who
				had left sided pulmonary vein (PV)
				isolation.

Rich <i>et al⁶⁸</i>	1988	CAD	100	Decreased HRV and ejection fraction
				were the best predictors of mortality
				(p<0.01). HRV was an independent
				predictor of mortality.
<u>Circle 1 52</u>	1000		2042	
Singh <i>et al⁵²</i>	1998	Hypertension	2042	HRV significantly lower in hypertensive
		(HTN)		men and women. LF associated with
				incident HTN in men (odds ratio (OR):
				1.38; 95% Cl 1.04-1.83 but not in women
				(OR: 1.12; 95% CI 0.86-1.46). Lower HRV
				associated with greater risk of
				developing HTN among normotensive
				men.
Stein <i>et al⁶⁰</i>	1993	Mitral	38	Heart rate, ultra low frequency (ULF), LF
		regurgitation		and LF/HF predicted mortality,
		(MR)		progression to surgery and development
				of permanent AF. SDANN was an
				independent predictor of poor outcomes
				(p=0.001).
Stein <i>et al⁶²</i>	1994	MR and AF	21	Reductions in measurements of ULF and
				HF were significant predictors of
				mortality or requirement for mitral valve
				surgery (p=0.02 and p=0.05 respectively).
van den	1997	AF	28	Baseline HRV was higher in AF group.
Berg <i>et al⁵⁹</i>				After administration of methylatropine,
				HRV neared zero in the control group
				whereas it returned to baseline in AF
				group. SD, RMSSD, LF and HF at baseline
				were significantly (p<0.05) correlated
				with vagal tone in both groups. HRV in
				patients with AF related to vagal tone.
7 volvo -+ - 169	1000		60	
Zysko <i>et al⁶⁹</i>	1999	CAD and PAF	68	No isolated stimulation of

	parasympathetic or sympathetic nervous
	system noted immediately prior to
	episode of PAF in patients with CAD.
	Cessation of PAF accompanied by
	increased RMSSD and pNN50.

Table 3 – Search strategy to look for articles containing atrial fibrillation and autonomicnervous system


	Searches	Results
1	atrial fibrillation.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]	204025
2	af.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]	129908
3	autonomic nervous system.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]	121449
4	autonomic dysfunction.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]	22430
5	1 or 2	262475
6	3 or 4	137164
7	5 and 6	2104

Table 4 – Search strategy to look for articles containing atrial fibrillation and heart rate variability

	Searches	Results
1	atrial fibrillation.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]	204025
2	af.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]	129908

3	heart rate variability.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm,	49842
	kf, ox, px, rx, an, ui, sy]	
4	HRV.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an,	26601
	ui, sy]	
5	1 or 2	262475
6	3 or 4	54174
7	5 and 6	1448

Figure 2 – Flow diagram of process for identification of suitable studies to include in the review



This article is protected by copyright. All rights reserved